Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Afatinib dimaleate by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma)....
Afatinib dimaleate by Boehringer Ingelheim International for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase II for Cutaneous Squamous Cell Carcinoma...
Afatinib dimaleate by Boehringer Ingelheim International for Refractory Multiple Myeloma: Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase II for Refractory Multiple Myeloma. According...